F-star Therapeutics (NASDAQ:FSTX) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of F-star Therapeutics (NASDAQ:FSTX) from a hold rating to a buy rating in a research report report published on Tuesday, Zacks.com reports. Zacks Investment Research currently has $5.25 price target on the stock.

According to Zacks, “F-star Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. F-star Therapeutics Inc., formerly known as Spring Bank Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. “

Several other analysts have also commented on the stock. HC Wainwright restated a buy rating and issued a $35.00 price objective on shares of F-star Therapeutics in a report on Tuesday, September 21st. LADENBURG THALM/SH SH lowered their price objective on shares of F-star Therapeutics from $27.00 to $15.00 and set a buy rating for the company in a report on Thursday, November 18th. William Blair restated a buy rating on shares of F-star Therapeutics in a report on Friday, October 22nd. Finally, Oppenheimer lifted their target price on shares of F-star Therapeutics from $30.00 to $33.00 and gave the company an outperform rating in a report on Friday, November 12th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of Buy and an average target price of $26.18.

NASDAQ FSTX opened at $4.53 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.62 and a quick ratio of 8.62. F-star Therapeutics has a 1 year low of $4.20 and a 1 year high of $15.50. The business’s 50-day moving average is $5.30 and its 200 day moving average is $6.38.

F-star Therapeutics (NASDAQ:FSTX) last issued its quarterly earnings data on Wednesday, November 10th. The company reported ($0.52) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.06. The company had revenue of $0.75 million during the quarter, compared to analysts’ expectations of $7.18 million. As a group, research analysts predict that F-star Therapeutics will post -2.34 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its holdings in shares of F-star Therapeutics by 1.4% during the third quarter. Russell Investments Group Ltd. now owns 177,286 shares of the company’s stock valued at $1,296,000 after purchasing an additional 2,513 shares during the last quarter. Morgan Stanley raised its holdings in F-star Therapeutics by 65.0% in the 2nd quarter. Morgan Stanley now owns 7,868 shares of the company’s stock worth $68,000 after acquiring an additional 3,100 shares during the last quarter. Renaissance Technologies LLC raised its holdings in F-star Therapeutics by 6.3% in the 2nd quarter. Renaissance Technologies LLC now owns 147,011 shares of the company’s stock worth $1,263,000 after acquiring an additional 8,700 shares during the last quarter. Geode Capital Management LLC raised its holdings in F-star Therapeutics by 11.6% in the 3rd quarter. Geode Capital Management LLC now owns 145,431 shares of the company’s stock worth $1,064,000 after acquiring an additional 15,152 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in F-star Therapeutics in the 3rd quarter worth approximately $114,000. Hedge funds and other institutional investors own 47.64% of the company’s stock.

About F-star Therapeutics

F-star Therapeutics, Inc is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm’s product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways.

Recommended Story: What is the Ex-Dividend Date in Investing?

Get a free copy of the Zacks research report on F-star Therapeutics (FSTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for F-star Therapeutics (NASDAQ:FSTX)

Receive News & Ratings for F-star Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F-star Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.